BCL10 nuclear expression and t(11;18)(q21;q21) indicate nonresponsiveness to Helicobacter pylori eradication of Chinese primary gastric MALT lymphoma.
The eradication of Helicobacter pylori (H. pylori) with antibiotics induces complete remission in 75% of patients with gastric MALT lymphoma. We investigated the efficacy of H. pylori eradication and assessed the predictive value of BCL10 nuclear expression and t(11;18)(q21;q21) regarding resistance to H. pylori eradication in primary gastric mucosa-associated lymphoid tissue lymphoma (MALT lymphoma) patients from mainland China. Twenty-two gastric MALT cases (Stage I(E)) underwent H. pylori eradication with antibiotics, and sequential endoscopic-bioptic follow-ups were performed and assessed with regular morphologic and immunohistochemical examinations. BCL10 nuclear expression and interphase fluorescence in situ hybridization (FISH) for MALT1 and API2/MALT1 were tested. Thirteen out of the 22 cases (59.1%) achieved complete regression (CR) after the eradication of H. pylori. The longest follow-up period in the 22 patients was 68 months, with 12 patients longer than 24 months. For the 13 CR patients, the longest follow-up period after H. pylori eradication was 53 months, with 6 patients longer than 24 months. BCL10 nuclear expression was detected by immunohistochemical staining in 9 cases, including 7 (77.8%) of 9 cases who showed no response (NR) and 2 (15.4%) of 13 patients who achieved CR following eradication therapy (P < 0.05). t(11;18)(q21;q21) was evaluated by interphase FISH in 18 cases including 11 CR and 7 NR patients after H. pylori eradication. t(11;18)(q21;q21) was found in 4 (57.1%) of 7 patients who showed NR following H. pylori eradication, but one in 11 CR patients (P < 0.05). A total of 59.1% of patients with early gastric MALT lymphoma recruited in this study achieved CR after H. pylori eradication. BCL10 nuclear expression and t(11;18)(q21;q21)-positive gastric MALT lymphomas are likely to be related to a failure to respond to H. pylori eradication in Chinese patients.
Dong
Gehong
G
Department of Pathology, Peking University Health Science Center, 100191, Beijing, People's Republic of China.
Liu
Cuiling
C
Department of Pathology, Peking University Health Science Center, 100191, Beijing, People's Republic of China.
Ye
Hongtao
H
Division of Molecular Histopathology, Department of Pathology, University of Cambridge, Cambridge, UK.|Department of Pathology, Guilin Medical College, 541004, Guilin, People's Republic of China.
Gong
Liping
L
Department of Pathology, Capital Medical University, 100069, Beijing, People's Republic of China.
Zheng
Jie
J
Department of Pathology, Peking University Health Science Center, 100191, Beijing, People's Republic of China.
Li
Min
M
Department of Pathology, Peking University Health Science Center, 100191, Beijing, People's Republic of China.
Huang
Xin
X
Department of Pathology, Peking University Health Science Center, 100191, Beijing, People's Republic of China.
Huang
Xuebiao
X
Department of Digestive Disease, Peking University Third Hospital, 100191, Beijing, People's Republic of China.
Huang
Yuanjie
Y
Department of Pathology, Peking University Health Science Center, 100191, Beijing, People's Republic of China.
Shi
Yunfei
Y
Department of Pathology, Peking University Health Science Center, 100191, Beijing, People's Republic of China.
Yin
Wenjuan
W
Department of Pathology, Peking University Health Science Center, 100191, Beijing, People's Republic of China.
Gao
Zifen
Z
Department of Pathology, Peking University Health Science Center, 100191, Beijing, People's Republic of China. wjshgao@bjmu.edu.cn.
D048868:Adaptor Proteins, Signal Transducing / Q000096:biosynthesis* / Q000235:genetics; D000293:Adolescent; D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000008:administration & dosage; D044466:Asian People; D000074018:B-Cell CLL-Lymphoma 10 Protein; D002681:China; D002880:Chromosomes, Human, Pair 11 / Q000235:genetics / Q000378:metabolism; D002887:Chromosomes, Human, Pair 18 / Q000235:genetics / Q000378:metabolism; D005260:Female; D005500:Follow-Up Studies; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D016481:Helicobacter Infections / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D016480:Helicobacter pylori; D006801:Humans; D018442:Lymphoma, B-Cell, Marginal Zone / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism* / Q000382:microbiology / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D013274:Stomach Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism* / Q000382:microbiology / Q000401:mortality / Q000473:pathology; D014178:Translocation, Genetic
D048868:Adaptor Proteins, Signal Transducing; D000900:Anti-Bacterial Agents; D000074018:B-Cell CLL-Lymphoma 10 Protein; C118591:BCL10 protein, human